AU
UK
CA
NZ
IND
US
Last update at 2024-07-25T17:02:29.617286Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -18.58700M | -24.21600M | -31.24700M | -17.05400M | -17.81600M |
| Minority interest | 0.00000M | 0.00000M | 0.00100M | -0.03100M | -0.03100M |
| Net income | -17.02600M | -22.69500M | -33.52600M | -21.42800M | -17.78800M |
| Selling general administrative | 0.00549M | 7.24M | 7.15M | 4.02M | 6.59M |
| Selling and marketing expenses | 4.68M | - | - | - | - |
| Gross profit | -0.80300M | -0.48400M | -0.31100M | -0.28000M | -0.26200M |
| Reconciled depreciation | 0.80M | 0.48M | 0.31M | 0.28M | 0.26M |
| Ebit | -15.89400M | -23.27200M | -26.81500M | -13.94200M | -15.68200M |
| Ebitda | -15.09100M | -23.65600M | -26.50400M | -14.22700M | -15.75400M |
| Depreciation and amortization | 0.80M | -0.38400M | 0.31M | -0.28500M | -0.07200M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -15.89400M | -23.27200M | -26.81500M | -13.94200M | -15.68200M |
| Other operating expenses | 15.89M | 23.27M | 26.82M | 13.94M | 15.68M |
| Interest expense | 1.25M | 1.60M | 4.43M | 4.37M | 2.53M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | -0.02800M |
| Interest income | - | - | - | - | - |
| Net interest income | -1.40700M | -2.46500M | -4.43200M | -4.93900M | -2.85900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.56100M | -1.52100M | 2.28M | 4.37M | -0.02800M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 15.09M | 23.27M | 26.82M | 13.94M | 15.68M |
| Cost of revenue | 0.80M | 0.48M | 0.31M | 0.28M | 0.26M |
| Total other income expense net | -2.69300M | -0.94400M | -4.43200M | -3.11200M | -2.13400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -17.02600M | -24.21600M | -31.24700M | -17.05400M | -17.78800M |
| Net income applicable to common shares | - | -24.21600M | -31.24600M | -17.05400M | -17.78800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.94M | 21.99M | 36.26M | 27.21M | 17.67M |
| Intangible assets | 2.64M | 2.65M | 2.76M | 2.67M | 2.40M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.84M | -0.00100M | 1.42M | -0.00100M | -0.00100M |
| Total liab | 15.85M | 23.90M | 30.56M | 20.38M | 25.20M |
| Total stockholder equity | -3.88100M | -1.87900M | 5.74M | 6.86M | -7.49500M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.77M | 4.47M | 6.28M | 3.11M | 0.45M |
| Common stock | 2.08M | 47.66M | 27.19M | 20.15M | 4.79M |
| Capital stock | 2.08M | 47.66M | 27.19M | 20.15M | 4.79M |
| Retained earnings | -19.38400M | -47.90500M | -49.11100M | -17.05400M | -17.78800M |
| Other liab | - | 0.18M | 1.12M | 0.19M | 0.14M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.17M | 1.25M | 0.40M | 0.36M |
| Cash | 5.57M | 11.05M | 23.93M | 5.85M | 6.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 12.37M | 19.35M | 23.14M | 18.36M | 19.66M |
| Current deferred revenue | 0.18M | 0.18M | 0.17M | - | 1.50M |
| Net debt | 2.70M | 1.07M | -8.55000M | 3.25M | 8.91M |
| Short term debt | 5.02M | 7.76M | 9.08M | 7.26M | 9.85M |
| Short long term debt | 3.47M | 7.48M | 8.86M | 7.26M | 9.85M |
| Short long term debt total | 8.27M | 12.13M | 15.38M | 9.10M | 15.24M |
| Other stockholder equity | 13.45M | -1.60900M | 27.73M | 17.78M | 45.22M |
| Property plant equipment | - | 0.58M | 0.56M | 0.11M | 0.18M |
| Total current assets | 8.85M | 18.58M | 31.69M | 24.01M | 14.71M |
| Long term investments | 0.03M | 0.05M | 0.08M | 0.09M | 0.04M |
| Net tangible assets | - | -4.53400M | 2.98M | 4.19M | -9.89500M |
| Short term investments | 0.37M | 0.59M | 1.23M | 12.92M | 0.47M |
| Net receivables | 2.44M | 5.36M | 5.12M | 5.21M | 7.85M |
| Long term debt | 2.42M | 4.18M | 6.07M | 1.83M | 5.40M |
| Inventory | - | 1.57M | - | 0.03M | 0.05M |
| Accounts payable | 5.39M | 6.94M | 7.61M | 7.99M | 7.87M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.02500M | -0.02500M | -0.07300M | -14.01300M | -39.72000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 20.15M | 4.79M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -0.00100M | 0.12M | 1.17M | 0.32M | 0.34M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3.09M | 3.41M | 4.57M | 3.20M | 2.97M |
| Capital lease obligations | 0.19M | 0.47M | 0.45M | - | 0.00000M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 0.37M | -0.01700M | 12.16M | -12.50000M | -12.50000M |
| Change to liabilities | - | -0.66500M | -0.38000M | 0.12M | 2.64M |
| Total cashflows from investing activities | - | -0.01700M | 12.16M | -12.71300M | -0.27800M |
| Net borrowings | - | 7.20M | 17.00M | 4.88M | 4.57M |
| Total cash from financing activities | 7.49M | 6.13M | 29.71M | 22.07M | 7.50M |
| Change to operating activities | - | -0.05300M | 0.12M | 0.05M | 0.11M |
| Net income | -17.02600M | -24.21600M | -31.24700M | -17.05400M | -17.78800M |
| Change in cash | -5.48600M | -12.87300M | 18.08M | -0.49000M | -8.06900M |
| Begin period cash flow | 11.05M | 23.93M | 5.85M | 6.34M | 14.41M |
| End period cash flow | 5.57M | 11.05M | 23.93M | 5.85M | 6.34M |
| Total cash from operating activities | -13.33300M | -18.98800M | -23.79500M | -9.86400M | -15.27300M |
| Issuance of capital stock | 5.54M | 0.00000M | 16.58M | 23.49M | - |
| Depreciation | 0.80M | 0.48M | 0.31M | 0.28M | 0.26M |
| Other cashflows from investing activities | - | - | 0.00400M | 0.00100M | 0.00400M |
| Dividends paid | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | - | 0.40M | 3.36M | 3.01M | 2.94M |
| Change to account receivables | 1.67M | -0.39800M | -3.36100M | -3.00700M | -2.94300M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 0.00100M | 8.22M | 16.73M | 2.55M | 7.55M |
| Change to netincome | - | 5.26M | 8.46M | 3.90M | 0.06M |
| Capital expenditures | 0.22M | 0.14M | 0.34M | 0.21M | 0.28M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.02600M | -1.33500M | 1.32M | 3.01M | -0.36100M |
| Stock based compensation | 0.81M | 5.57M | 3.42M | 0.79M | 0.06M |
| Other non cash items | 4.18M | 0.51M | 0.48M | 4.52M | 3.31M |
| Free cash flow | -13.55300M | -19.12900M | -24.13900M | -10.07800M | -15.55500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| BPTS Biophytis |
- -% | - | - | - | - | 2.27 | -0.1897 | |
| NVO Novo Nordisk A/S |
2.69 6.23% | 45.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.60 3.69% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
15.16 3.36% | 466.79 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.56 0.42% | 612.50 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Sorbonne University, Paris, France, 75005
| Name | Title | Year Born |
|---|---|---|
| Mr. Stanislas Veillet Ph.D. | Chairman & CEO | 1965 |
| Mr. Philippe J. Rousseau | Chief Financial Officer | 1971 |
| Mr. Waly Dioh | Chief Operating Officer | 1969 |
| Dr. Pierre J. Dilda | Chief Scientific Officer | 1970 |
| Dr. Rene Lafont | Scientific Advisor & Member of Scientific Advisory Board | 1946 |
| Mr. Benoit Canolle | Chief Bus. Officer | 1978 |
| Mr. Rob van Maanen FFPM, M.B.A., M.D. | Chief Medical Officer | 1970 |
| Ms. _ Teylan | Financial Controller | NA |
| Mr. Stanislas Veillet Ph.D. | Chairman of the Board & CEO | 1965 |
| Mr. Nicolas Fellmann | Chief Financial Officer | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...